Improved metabolic control by DPP-4 inhibition in T2DM patients is linked with reduced glucagon levels and, in spite of the lower glycaemia, unaltered insulin levels (Ahren et al., 2004). This evidence concerns the gene INS and type 2 diabetes mellitus.